Compare Li Auto Inc (LI) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Li Auto Inc vs Recursion Pharmaceuticals Inc — how do they compare? Li Auto Inc trades at $12.26 (market cap $12.43B), while Recursion Pharmaceuticals Inc trades at $3.08 (market cap $1.53B). The key difference: Li Auto Inc is far larger — about 8.1× Recursion Pharmaceuticals Inc's market cap. Which is the better fit depends on your goals.
| LI | RXRX | |
|---|---|---|
Market Cap | $12.43B | $1.53B |
Sector | Consumer Cyclical | Health |
52-Week High | $30.84 | $6.79 |
52-Week Low | $11.74 | $2.84 |
Enterprise Value | $1.34B | $946.50M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Li Auto (LI) trades at $12.21, down 1.45% on the day, amid a bearish technical signal and mixed earnings history. The company reported a net income margin of -1.66% for 2025, with revenue declining to $112.31 billion from $144.5 billion in 2024. Recent news includes the launch of new SUV models like the Li L6 in July 2026, aiming to bolster sales in a competitive EV market. Cash flow trends show operational challenges, with negative operating cash flow of $8.61 billion in 2025, though 2026 projections indicate a potential recovery.
Outlook remains cautious due to profitability concerns and intense competition, but analyst consensus suggests upside with a $14.80 price target. Risks include execution hurdles and macroeconomic pressures, yet institutional sentiment leans neutral with 50% hold ratings. Investors should weigh near-term volatility against long-term growth potential in China's EV sector.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Li Auto Inc
Li Auto is a leading Chinese NEV manufacturer that designs, develops, manufactures, and sells premium smart NEVs. The company started volume production of its first model Li One in November 2019. The model is a six-seater, large, premium plug-in electric SUV equipped with a range extension system and advanced smart vehicle solutions. It sold over 90,000 EVs in 2021, accounting for about 2.7% of China's passenger new energy vehicle market. Beyond Li One, the company will expand its product line, including both BEVs and PHEVs, to target a broader consumer base.
Read more on LI →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
